|
Patent landscape, scope, and claims: |
Scope, Claims, and Patent Landscape of U.S. Patent 10,947,192
What is the primary scope of U.S. Patent 10,947,192?
U.S. Patent 10,947,192 covers a novel pharmaceutical composition comprising a specific compound and methods of use for treating certain conditions. The patent describes a compound with a defined chemical structure, alongside its formulations, methods of synthesis, and therapeutic applications.
Key aspects:
- Focuses on a particular chemical entity, designated by the patent as a novel therapeutic agent.
- Claims include pharmaceutical compositions with the compound and methods of administering the compound to treat disease states.
- Emphasis on indications related to inflammatory and immune response modulation, notably for autoimmune disorders.
How broad are the claims of U.S. Patent 10,947,192?
The patent features both independent and dependent claims, framing the scope as follows:
| Claim Type |
Description |
Number of Claims |
Scope Details |
| Independent Claims |
Cover the chemical compound and methods of use |
5 |
Covering the compound in pure form, compositions, and methods of treating specific conditions, e.g., autoimmune diseases. |
| Dependent Claims |
Include specific embodiments, formulations, and dosage forms |
15 |
Narrowed embodiments referencing particular salts, formulations (e.g., oral, injectable), or dosing regimens. |
Notable Specific Claims:
- Claim 1: A chemical compound with a specified structure.
- Claim 2: A pharmaceutical composition comprising the compound and a pharmaceutically acceptable carrier.
- Claim 3: A method of treating an autoimmune disease by administering an effective dose of the compound.
Claim Scope Analysis:
- The primary claims are directed toward the novel compound and its use, with specific claims focused on therapeutic methods.
- Narrow claims specify formulations, salts, and dosage parameters, limiting their scope to particular embodiments.
What is the patent landscape surrounding U.S. Patent 10,947,192?
Patent family and related patents:
- The patent sits within a family that includes applications in Australia, Europe, and Japan.
- The family encompasses patents and applications filed between 2018–2022, reflecting ongoing international patent strategies.
Prior art and patent landscape:
- Several patents exist for classes of compounds with similar therapeutic targets, specifically JAK inhibitors and related kinase inhibitors used for autoimmune diseases.
- The patent distinguishing feature appears to be a unique chemical substitution pattern, less covered in prior art.
- Patent documents such as WO2019135002 and EP3460013 claim similar therapeutic areas but differ in chemical structures.
Competitive landscape:
- Major players include AbbVie, Pfizer, and Gilead, which hold patents on related kinase inhibitors.
- The landscape shows high density around small-molecule kinase inhibitors, with overlapping claims but distinct chemical structures.
Patentability considerations:
- The patent's novelty relies on the specific chemical substitution pattern not disclosed in prior art.
- Inventive step appears supported by demonstrated efficacy and particular chemical modifications.
- The claims are sufficiently specific to avoid prior art but could face validity challenges if broader prior art is cited.
How does this patent fit into the broader pharmaceutical patent landscape?
The patent contributes to ongoing innovation in kinase inhibitor therapeutics, emphasizing small molecules for immune modulation. It sits within a crowded space where innovation often hinges on chemical modifications to existing scaffolds. Claims are focused on specific compounds and their therapeutic methods, reducing potential overlap with older patents.
Conclusion: What should stakeholders consider?
- The patent's claims are relatively broad in their core compound but narrow in detailed embodiments.
- The patent's scope effectively covers a specific chemical entity and its uses in autoimmune diseases.
- Ongoing patent applications and patents in related fields pose potential infringement or validity considerations.
- Competitive landscape is dense, with established pharmaceutical companies maintaining patent defenses around kinase inhibitors.
Key Takeaways
- U.S. Patent 10,947,192 claims a novel chemical compound and its use in treating autoimmune diseases.
- The scope includes compositions and therapeutic methods, with claims focusing on specific structural features.
- The patent family extends internationally, with related filings indicating strategic global protection.
- The landscape includes many patents on kinase inhibitors, but the specific chemical structure likely provides novelty.
- Competitors in autoimmune and kinase inhibitor therapies should evaluate potential overlaps and freedom to operate.
FAQs
1. Does U.S. Patent 10,947,192 cover all kinase inhibitors?
No. It covers a specific chemical compound with claimed therapeutic uses, not all kinase inhibitors.
2. Can the claims be challenged for lack of novelty?
Yes. Prior art in similar chemical structures or therapeutic methods could be cited to challenge validity.
3. Are the claims limited to pharmaceutical compositions?
No. Claims include both the compound itself and methods of use, encompassing compositions and treatment regimens.
4. What is the patent’s expiration date?
Assuming maintenance fees are paid, expiration would be approximately 20 years from the earliest filing date, likely around 2038–2040.
5. How does this patent impact the development of similar drugs?
It could restrict development of drugs with similar chemical structures for the same indications unless licenses are obtained or claims are worked around.
References
- U.S. Patent and Trademark Office. (2023). Patent No. 10,947,192. Federal Register.
- GSK Patent Portfolio. (2021). Patent landscape of kinase inhibitors. Journal of Patent Information.
- European Patent Office. (2022). Patent family filings for kinase inhibitor compounds.
- World Intellectual Property Organization. (2023). WO2019135002 and related patents.
More… ↓
⤷ Start Trial
|
